Mycophenolate mofetil in the treatment of lupus nephritis

References

• AdamsAMacDermottEJLehmanTJ2006Pharmacotherapy of Lupus Nephritis in Children: A Recommended Treatment ApproachDrugs66119120716827597
   PubMed Web of Science ®Google Scholar
• AllisonACAlmquistSJMullerCD1991In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443Transplant Proc231042063415
   PubMed Web of Science ®Google Scholar
• AllisonACEuguiEM2000Mycophenolate mofetil and its mechanisms of actionImmunopharmacology478511810878285
   PubMed Web of Science ®Google Scholar
• AustinHAIlleiGG2005Membranous lupus nephritisLupus14657115732291
   PubMed Web of Science ®Google Scholar
• AustinHAIIIKlippelJHBalowJE1986Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugsN Engl J Med31461493511372
   PubMed Web of Science ®Google Scholar
• BastianHMRosemanJMMcGwinGJrfor the LUMINA Study Group2002Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosisLupus1115216012004788
   PubMed Web of Science ®Google Scholar
• BlahetaRALeckelKWittigB1999Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T cellsTransplant Proc311250210083559
   PubMed Web of Science ®Google Scholar
• BoumpasDTAustinHAIIIVaughnEM1992Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritisLancet34074151356175
   PubMed Web of Science ®Google Scholar
• BuddeKKnollGCurtisJ2006Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic)Clin Nephrol661031116939066
   PubMed Web of Science ®Google Scholar
• BullinghamRENichollsAJKammBR1998Clinical pharmacokinetics of mycophenolate mofetilClin Pharmacokinet34429559646007
   PubMed Web of Science ®Google Scholar
• BurattiSSzerSSpencerCH2001Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosusJ Rheumatol282103811550982
   PubMed Web of Science ®Google Scholar
• CameronJS1999Lupus nephritisJ Am Soc Nephrol104132410215343
   PubMed Web of Science ®Google Scholar
• CarrSFPappEWuJC1993Characterization of human type I and type II IMP dehydrogenasesJ Biol Chem26827286907903306
   PubMed Web of Science ®Google Scholar
• ChanLMulgaonkarSWalkerR2006Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric coated mycophenolate sodiumTransplantation811290716699457
   PubMed Web of Science ®Google Scholar
• ChanTMLiFKTangCS2000Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study GroupN Engl J Med34311566211036121
   PubMed Web of Science ®Google Scholar
• ChanTMTseKCTangCS2005Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritisJ Am Soc Nephrol1610768415728784
   PubMed Web of Science ®Google Scholar
• ColicMStojic-VukanicZPavlovicB2003Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cellsClin Exp Immunol13463912974756
   PubMed Web of Science ®Google Scholar
• ContrerasGPardoVLeclercqB2004Sequential therapies for proliferative lupus nephritisN Engl J Med3509718014999109
   PubMed Web of Science ®Google Scholar
• ContrerasGTozmanENaharN2005Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamideLupus14Suppl 1S33815803929
   PubMed Web of Science ®Google Scholar
• CornaDMorigiMFacchinettiD1997Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune diseaseKidney Int51158399150476
   PubMed Web of Science ®Google Scholar
• DanchenkoNSatiaJAAnthonyMS2006Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burdenLupus153081816761508
   PubMed Web of Science ®Google Scholar
• EMEA (European Medicines Agency)2008Cellcept, European public assessment report 2008 [online]. Accessed 1 Feburary 2008. URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/cellcept/cellcept.htm
   Google Scholar
• FlancRSRobertsMAStrippoliGF2004Treatment of diffuse proliferative lupus nephritis: a metaanalysis of randomized controlled trialsAm J Kidney Dis4319720814750085
   PubMed Web of Science ®Google Scholar
• Flores-SuárezLFVillaAR2004Preliminary results of an open label randomised clinical trial comparing mycophenylate mofetil (MMF) vs intravenous cyclophosphamide as induction therapy for severe lupus nephritisArthritis Rheum50SupplS4141029
   Google Scholar
• FuYFLiuGL2001Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclophosphamide and cyclosporineClin Nephrol553182111334319
   PubMed Web of Science ®Google Scholar
• FurnessPNTaubN2006Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis – A UK-wide studyAm J Surg Pathol301030516861976
   PubMed Web of Science ®Google Scholar
• GinzlerEMAppelGBDooleyMA2007Mycophenolate Mofetil and Intravenous Cyclophosphamide in the Aspreva Lupus Management Study (ALMS): Efficacy by Racial GroupArthritis Rheum54Suppl AbstractL13
   Google Scholar
• GinzlerEMDooleyMAAranowC2005Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritisN Engl J Med35322192816306519
   PubMed Web of Science ®Google Scholar
• GoldblumR1993Therapy of rheumatoid arthritis with mycophenolate mofetilClin Exp Rheumatol11Suppl 8S117S198324935
   PubMed Web of Science ®Google Scholar
• GourishankarSMcDermidJCJhangriGS2004Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive eraAm J Transplant41081514678041
   PubMed Web of Science ®Google Scholar
• GourleyMFAustinHAIIIScottD1996Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trialAnn Intern Med125549578815753
   PubMed Web of Science ®Google Scholar
• HoussiauFAVasconcelosCD’CruzD2002Immunosuppressive therapy in lupus nephritisArthritis Rheum4621213112209517
   PubMed Web of Science ®Google Scholar
• HoussiauFAVasconcelosCD’CruzD2004Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis TrialArthritis Rheum5039344015593207
   PubMed Web of Science ®Google Scholar
• JonssonCASvenssonLCarlstenH1999Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr miceClin Exp Immunol1165344110361247
   PubMed Web of Science ®Google Scholar
• KapitsinouPPBoletisJNSkopouliFN2004Lupus nephritis: treatment with mycophenolate mofetilRheumatology, (Oxford)433778014963204
   PubMed Web of Science ®Google Scholar
• KarimMYPisoniCNFerroL2005Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathyRheumatology, (Oxford)4413172116049051
   PubMed Web of Science ®Google Scholar
• KasitanonNPetriMHaasM2008Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 casesLupus1740518089682
   PubMed Web of Science ®Google Scholar
• KitiyakaraCOphascharoensukVChangsirikulchaiS2008Treatment of lupus nephritis and primary glomerulonephritis with enteric-coated mycophenolate sodiumClin Nephrol699010118218302
   PubMed Web of Science ®Google Scholar
• LagaraineCLebranchuY2003Effects of immunosuppressive drugs on dendritic cells and tolerance inductionTransplantation7537S42S12819489
   PubMed Web of Science ®Google Scholar
• LauKLJonesDPHastingsMC2006Short-term outcomes of severe lupus nephritis in a cohort of predominantly African-American childrenPediatr Nephrol216556216570203
   PubMed Web of Science ®Google Scholar
• Le MeurYBüchlerMThierryA2007Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantationAm J Transplant7249650317908276
   PubMed Web of Science ®Google Scholar
• LuiSLTsangRWongD2002Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr miceLupus11411812195781
   PubMed Web of Science ®Google Scholar
• McMurrayRWElbourneKBLagooA1998Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB × NZW F1 mouse model of systemic lupus erythematosusJ Rheumatol252364709858431
   PubMed Web of Science ®Google Scholar
• MooreRADerryS2006Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritisArt Res Ther8R182
   PubMed Web of Science ®Google Scholar
• MorathCSchwengerVBeimlerJ2006Antifibrotic actions of mycophenolic acidClin Transplant20Suppl 1725917100698
   PubMed Web of Science ®Google Scholar
• NatsumedaYOhnoSKawasakiH1990Two distinct cDNAs for human IMP dehydrogenaseJ Biol Chem265529251969416
   PubMed Web of Science ®Google Scholar
• NowakIShawLM1995Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamicsClin Chem41101177600680
   PubMed Web of Science ®Google Scholar
• OngLMHooiLSLimTO2005Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritisNephrology, (Carlton)105041016221103
   PubMed Web of Science ®Google Scholar
• ParedesA2007Can mycophenolate mofetil substitute cyclophosphamide treatment of pediatric lupus nephritis?Pediatr Nephrol2210778217370094
   PubMed Web of Science ®Google Scholar
• PatelMClarkeAMBruceIN2006The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradientArthritis Rheum542963916947632
   PubMed Web of Science ®Google Scholar
• PecoraroCMalgieriGD’ArmientoM2005Treatment of childhood lupus nephritis with mycophenolate mofetil: clinical and histopathological studyJ Am Soc Nephrol16557A
   Web of Science ®Google Scholar
• Perez-AytesALedoABosoV2008In utero exposure to mycophenolate mofetil: a characteristic phenotype?Am J Med Genet1461718074358
   PubMed Web of Science ®Google Scholar
• RamosMAPineraCSetienMA2003Modulation of autoantibody production by mycophenolate mofetil: effects on (NZB × NZW) F1 miceNephrol Dial Transplant188788312686658
   PubMed Web of Science ®Google Scholar
• RoosNPoulalhonNFargeD2007In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetilJ Pharmacol Exp Ther321583917272676
   PubMed Web of Science ®Google Scholar
• SalvadoriMHolzerHde MattosA2004Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patientsAm J Transplant4231614974944
   PubMed Web of Science ®Google Scholar
• SendaMDeLustroBEuguiE1995Y. Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cellsTransplantation60114387482723
   PubMed Web of Science ®Google Scholar
• SinclairAAppelGDooleyMA2007Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS)Lupus169728018042591
   PubMed Web of Science ®Google Scholar
• SongATAbdalaEBonazziPR2006Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients?A mini-reviewBraz J Infect Dis10132816878265
   PubMedGoogle Scholar
• SpetieDNTangYRovinBH2004Mycophenolate therapy of SLE membranous nephropathyKidney Int662411515569333
   PubMed Web of Science ®Google Scholar
• TragerJWardMM2001Mortality and causes of death in systemic lupus erythematosusCurr Opin Rheumatol133455111604587
   PubMed Web of Science ®Google Scholar
• TseKCTangCSOLioWI2006Quality of life comparison between corticosteroid-and-mycofenolate mofetil and corticosteroid-and-oral cyclophosphamide in the treatment of severe lupus nephritisLupus15371916830884
   PubMed Web of Science ®Google Scholar
• Van BruggenMCWalgreenBRijkeTP1998Attenuation of murine lupus nephritis by mycophenolate mofetilJ Am Soc Nephrol91407159697662
   PubMed Web of Science ®Google Scholar
• van GelderTHilbrandsLBVanrenterghemY1999A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantationTransplantation68261610440399
   PubMed Web of Science ®Google Scholar
• van GelderTShawLM2005The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantationTransplantation802 SupplS2445316251857
   PubMed Web of Science ®Google Scholar
• van HestRMMathotRAPescovitzMD2006Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipientsJ Am Soc Nephrol178718016452491
   PubMed Web of Science ®Google Scholar
• WalshMJamesMJayneD2007Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysisClin J Am Soc Nephrol29687517702723
   PubMed Web of Science ®Google Scholar
• WangKZhangHLiY2004Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic reviewTransplant Proc3620687015518748
   PubMed Web of Science ®Google Scholar
• WeberLTShipkovaMArmstrongVW2002The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the German Study Group on Mycophenolate Mofetil TherapyJ Am Soc Nephrol137596811856782
   PubMed Web of Science ®Google Scholar
• WeeningJJD’AgatiVDSchwartzMM2004The classification of glomerulonephritis in systemic lupus erythematosus revisitedJ Am Soc Nephrol152415014747370
   PubMed Web of Science ®Google Scholar
• WilsonECFJayneDRWDellowE2007The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritisRheumatology46109610117409128
   PubMed Web of Science ®Google Scholar
• YeZTanYHHongXP2001MMF vs CTX in the treatment of severe SLE patientsLupus10Suppl 1S99274
   Google Scholar
• YokoyamaHWadaTHaraA2004The outcome and a new ISN/RPS 2003 classification of lupus nephritis in JapaneseKidney Int662382815569330
   PubMed Web of Science ®Google Scholar
• YuCCYangCWWuMS2001Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr miceJ Lab Clin Med138697711433230
   PubMed Web of Science ®Google Scholar
• ZhuBChenNLinY2007Mycophenolate mofetil in induction therapy of severe lupus nephritis: a meta-analysis of randomized controlled trialsNephrol Dial Transplant2219334217405792
   PubMed Web of Science ®Google Scholar
• ZojaCBenigniANorisM2001Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritisKidney Int606536311473648
   PubMed Web of Science ®Google Scholar